Patents by Inventor Joseph M. Salvino

Joseph M. Salvino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240166626
    Abstract: The ?2-adrenergic receptor (?2AR) is a primary target in the treatment of airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Since ?-agonist treatment of airway disease can have severe side effects, compounds that attenuate the side effects of ?-agonists have been identified via their ability to inhibit ?2AR interaction with ?-arrestins. These compounds are specific for the ?2AR and effectively protect against the desensitization observed with ?-agonist treatment in model cells and airway tissue. The present disclosure provides compounds and methods for treating airway disease, such as but not limited to COPD and/or asthma.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 23, 2024
    Inventors: Michael Joseph IPPOLITO, Nathan Ross HOPFINGER, Charles P. SCOTT, Roger S. ARMEN, Jeffrey Lee BENOVIC, Joseph M. Salvino
  • Publication number: 20230102212
    Abstract: Compounds, compositions and methods for suppressing an immune response to polyethylene glycol (PEG) are provided.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Applicant: aAb Therapeutics, LLC
    Inventors: Vidal F. de la Cruz, Joseph M. Salvino
  • Publication number: 20220402938
    Abstract: The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
    Type: Application
    Filed: June 23, 2022
    Publication date: December 22, 2022
    Inventors: Sandhya Kortagere, Andreia C. K. Mortensen, Ole V. Mortensen, Joseph M. Salvino
  • Publication number: 20220267308
    Abstract: The present disclosure provides in one aspect compounds of Formula I. In certain embodiments, the compounds of the disclosure are useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compounds of the disclosure stimulate a glutamate transporter.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Inventors: Joseph M. Salvino, Andreia C.K. Mortensen, Valli Venkata Srikanth Yellamelli
  • Patent number: 11377452
    Abstract: The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: July 5, 2022
    Assignee: Drexel University
    Inventors: Sandhya Kortagere, Andreia C. K. Mortensen, Ole V. Mortensen, Joseph M. Salvino
  • Publication number: 20220144845
    Abstract: The disclosure provides compounds of formula (II) having the structure: Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Joseph M. SALVINO, Xin FENG, Alessandro FATATIS, Fei SHEN, Olimpia MEUCCI
  • Patent number: 11267817
    Abstract: The disclosure provides compounds of formula (I) having the structure: Compounds of formula (I) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: March 8, 2022
    Assignee: Drexel University
    Inventors: Joseph M. Salvino, Xin Feng, Alessandro Fatatis, Fei Shen, Olimpia Meucci
  • Publication number: 20210113613
    Abstract: Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with fenofibric acid (FFA), an FFA prodrug, or a derivative thereof that has PPAR-? agonist activity. These compounds promote the use of fatty acid catabolism rather than glucose for energy and promote enhanced recovery of, and biomass production by, the pre-treated T cells. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor an immunotherapeutic composition targeting an antigen or ligand on the tumor cell and the pretreated T cells. The method may also employ co-administration of a checkpoint inhibitor. Novel compositions comprise the pre-treated T cells. Novel FFA prodrugs are provided.
    Type: Application
    Filed: August 1, 2018
    Publication date: April 22, 2021
    Inventors: HILDEGUND C.J. ERTL, Joseph M. Salvino, Valli V.S. Yellamelli
  • Publication number: 20200255445
    Abstract: The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 13, 2020
    Inventors: Sandhya Kortagere, Andreia C.K. Mortensen, Ole V. Mortensen, Joseph M. Salvino
  • Publication number: 20200062768
    Abstract: The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 27, 2020
    Inventors: Joseph M. SALVINO, Xin FENG, Alessandro FATATIS, Fei SHEN, Olimpia MEUCCI
  • Patent number: 10414771
    Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 17, 2019
    Assignees: Drexel University, Alliance Discovery, Inc.
    Inventors: Alessandro Fatatis, Joseph M. Salvino, Olimpia Meucci, Whitney L. Gladney
  • Publication number: 20190241578
    Abstract: The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 8, 2019
    Inventors: Sandhya KORTAGERE, Ole MORTENSEN, Andreia C. K. MORTENSEN, Joseph M. SALVINO
  • Publication number: 20190240202
    Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 8, 2019
    Inventors: Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
  • Patent number: 10314795
    Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 11, 2019
    Assignee: Drexel University
    Inventors: Felix J. Kim, Joseph M. Salvino
  • Patent number: 10307406
    Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 4, 2019
    Assignees: The Wistar Institute of Anatomy and Biology, Drexel University
    Inventors: Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
  • Patent number: 10287290
    Abstract: The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 14, 2019
    Assignee: Drexel University
    Inventors: Sandhya Kortagere, Ole Mortensen, Andreia C. K. Mortensen, Joseph M. Salvino
  • Publication number: 20180235910
    Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
    Type: Application
    Filed: September 22, 2017
    Publication date: August 23, 2018
    Inventors: Felix J. KIM, Joseph M. Salvino
  • Publication number: 20180099972
    Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 12, 2018
    Inventors: Alessandro Fatatis, Joseph M. Salvino, Olimpia Meucci, Whitney L. Gladney
  • Patent number: 9889102
    Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: February 13, 2018
    Assignee: Drexel University
    Inventors: Felix J. Kim, Joseph M. Salvino
  • Patent number: 9856260
    Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 2, 2018
    Assignees: Drexel University, Alliance Discovery, Inc.
    Inventors: Alessandro Fatatis, Joseph M. Salvino, Olimpia Meucci, Whitney L. Gladney